Sign In
Buy PLX
Protalix BioTherapeutics Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.220 |
| EPS Surprise | 2,300.00% |
| Revenue estimate | 11.5M |
| Revenue actual | 33.75M |
| Revenue Surprise | 193.48% |
| Release date | Mar 18, 2026 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0700 |
| EPS Surprise | -800.00% |
| Revenue estimate | 18.3M |
| Revenue actual | 9.124M |
| Revenue Surprise | -50.14% |
| Release date | Nov 13, 2025 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0300 |
| EPS Surprise | -50.00% |
| Revenue estimate | 14.244M |
| Revenue actual | 17.851M |
| Revenue Surprise | 25.32% |
| Release date | Aug 14, 2025 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0020 |
| EPS Surprise | -93.27% |
| Revenue estimate | 13.486M |
| Revenue actual | 15.658M |
| Revenue Surprise | 16.11% |
Last 4 Quarters for Protalix BioTherapeutics
Below you can see how PLX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $1.52 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0020 |
| EPS surprise | -93.27% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $1.54 |
| Aug 11, 2025 | $1.61 |
| Aug 12, 2025 | $1.64 |
| Aug 13, 2025 | $1.61 |
| Aug 14, 2025 | $1.52 |
| Aug 15, 2025 | $1.48 |
| Aug 18, 2025 | $1.54 |
| Aug 19, 2025 | $1.53 |
| Aug 20, 2025 | $1.57 |
| 4 days before | -1.30% |
| 4 days after | 3.29% |
| On release day | -2.63% |
| Change in period | 1.95% |
| Release date | Nov 13, 2025 |
| Price on release | $1.94 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0300 |
| EPS surprise | -50.00% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $2.19 |
| Nov 10, 2025 | $2.13 |
| Nov 11, 2025 | $2.13 |
| Nov 12, 2025 | $2.14 |
| Nov 13, 2025 | $1.94 |
| Nov 14, 2025 | $1.86 |
| Nov 17, 2025 | $1.89 |
| Nov 18, 2025 | $1.88 |
| Nov 19, 2025 | $1.77 |
| 4 days before | -11.42% |
| 4 days after | -8.76% |
| On release day | -4.12% |
| Change in period | -19.18% |
| Release date | Mar 18, 2026 |
| Price on release | $2.21 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0700 |
| EPS surprise | -800.00% |
| Date | Price |
|---|---|
| Mar 12, 2026 | $2.79 |
| Mar 13, 2026 | $2.83 |
| Mar 16, 2026 | $2.87 |
| Mar 17, 2026 | $2.79 |
| Mar 18, 2026 | $2.21 |
| Mar 19, 2026 | $2.23 |
| Mar 20, 2026 | $2.14 |
| Mar 23, 2026 | $2.13 |
| Mar 24, 2026 | $2.07 |
| 4 days before | -20.79% |
| 4 days after | -6.33% |
| On release day | 0.90% |
| Change in period | -25.81% |
| Release date | May 13, 2026 |
| Price on release | $1.93 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.220 |
| EPS surprise | 2,300.00% |
| Date | Price |
|---|---|
| May 07, 2026 | $1.98 |
| May 08, 2026 | $1.94 |
| May 11, 2026 | $1.94 |
| May 12, 2026 | $1.91 |
| May 13, 2026 | $1.93 |
| May 14, 2026 | $2.00 |
| May 15, 2026 | $1.98 |
| May 18, 2026 | $1.91 |
| May 19, 2026 | $1.90 |
| 4 days before | -2.53% |
| 4 days after | -1.55% |
| On release day | 3.63% |
| Change in period | -4.04% |
Protalix BioTherapeutics Earnings Call Transcript Summary of Q1 2026
Protalix reported Q1 2026 total revenue of $33.8M, driven primarily by a $25M milestone from partner Chiesi after European approval of an every-4-weeks dosing regimen for Elfabrio. Product revenues were $7.4M (down YoY due to timing and inventory patterns at Elelyso partners), while R&D spend rose to $5.4M as the company advances the PRX-115 Phase II RELEASE study. Net income was $18.3M ($0.23/share) vs. a loss in the prior-year period. Cash and equivalents totaled approximately $51M with no debt or warrants, and management reaffirmed 2026 guidance of $78M–$83M total revenue (including the $25M milestone), projecting Elfabrio revenues of ~$33M–$35M (ex-milestones) and Elelyso revenues of ~$20M–$23M. Management expects enrollment in the PRX-115 trial to complete by year-end 2026 with topline results in H2 2027, and they reiterated confidence that Elfabrio could capture 15%–20% of the global Fabry market by 2031. Near-term upside depends on Chiesi’s country-by-country reimbursement rollout for the new dosing regimen, with most commercial impact expected in H2 2026.
